BioCardia Enrolls First Patient in Phase 3 CardiAMP HF II Trial.

BioCardia has announced the first patient enrolled in its Phase 3 CardiAMP HF II clinical trial at Henry Ford Health for patients with ischemic heart failure of reduced ejection fraction. The trial aims to investigate the efficacy of the CardiAMP cell therapy in treating this condition. Dr. Gerald Koenig, Principal Investigator, noted that previous studies have shown promising results with autologous cell therapy in patients with HFrEF, particularly those with elevated biomarkers of heart stress.